IMV (TSE:IMV) will be issuing its quarterly earnings data before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of C($0.15) per share for the quarter.
IMV (TSE:IMV) last released its earnings results on Thursday, March 21st. The company reported C($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of C($0.09) by C($0.08). The firm had revenue of C$0.13 million during the quarter.
IMV opened at C$5.95 on Thursday. The firm has a market capitalization of $301.05 million and a PE ratio of -11.88. IMV has a 12-month low of C$3.95 and a 12-month high of C$9.49. The company has a quick ratio of 2.23, a current ratio of 2.57 and a debt-to-equity ratio of 221.17.
A number of equities analysts have recently weighed in on IMV shares. National Bank Financial dropped their price target on shares of IMV from C$12.00 to C$11.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 5th. HC Wainwright reaffirmed a “buy” rating on shares of IMV in a research note on Monday, March 25th.
IMV Inc, a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Featured Story: Google Finance Portfolio